Literature DB >> 6522148

Biochemical studies of a patient with hereditary hepatorenal tyrosinemia: evidence of glutathione deficiency.

E Stoner, H Starkman, D Wellner, V P Wellner, S Sassa, A B Rifkind, A Grenier, P G Steinherz, A Meister, M I New.   

Abstract

Metabolic and enzymatic studies in a patient with hereditary tyrosinemia demonstrated for the first time a deficiency of erythrocyte and hepatic glutathione. Markedly decreased hepatic fumarylacetoacetate hydrolase activity was demonstrated in this patient. The activities of hepatic enzymes not involved in tyrosine metabolism were also determined. Assay of mixed function oxidase activity demonstrated low levels of aryl hydrocarbon hydroxylase and 7-ethoxycoumarin deethylase, suggesting decreased hepatic detoxification capacity. 5-Aminolevulinic acid dehydratase activity was undetectable. Succinylacetone (4,6-dioxoheptanoic acid), an abnormal metabolic product secondary to fumarylacetoacetate hydrolase deficiency was found in serum and urine. Succinylacetone was demonstrated to inhibit 5-aminolevulinic acid dehydratase in vitro, as did the urine, plasma, and red cell lysates of the patient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6522148     DOI: 10.1203/00006450-198412000-00023

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

Review 1.  Changing concepts: liver replacement for hereditary tyrosinemia and hepatoma.

Authors:  T E Starzl; B J Zitelli; B W Shaw; S Iwatsuki; J C Gartner; R D Gordon; J J Malatuck; I J Fox; A H Urbach; D H Van Thiel
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

2.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

3.  Abnormal glutathione conjugation in patients with tyrosinaemia type I.

Authors:  T M Mulders; D J Bergman; B T Poll-The; G P Smit; D D Breimer; G J Mulder; M Duran; J A Smeitink
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

4.  Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.

Authors:  D Phaneuf; M Lambert; R Laframboise; G Mitchell; F Lettre; R M Tanguay
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

5.  Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I.

Authors:  M J Prieto-Alamo; F Laval
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 6.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Clinical features and diagnostic approach in type I tyrosinaemia in an infant with cytomegaly virus infection and bacterial sepsis.

Authors:  M Wabitsch; F Pohlandt; D Leupold; R Berger; E Mönch; E Heinze; W Teller
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

8.  Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.

Authors:  S Manabe; S Sassa; A Kappas
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

9.  Oral loading of homogentisic acid in controls and in obligate heterozygotes for hereditary tyrosinemia type I.

Authors:  C Laberge; A Lescault; A Grenier; J Morrisette; R Gagné; P Gadbois; J Halket
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

10.  Tyrosinaemia type 1 and glutathione synthetase deficiency: two disorders with reduced hepatic thiol group concentrations and a liver 4-fumarylacetoacetate hydrolase deficiency.

Authors:  A J Lloyd; R G Gray; A Green
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.